HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

GMU Investigators Create Highly Sensitive Diagnostic Tool for TB in HIV-Negative Patients

Investigators from George Mason University have developed another diagnostic method for tuberculosis (TB), a highly sensitive and specific urine test.

In 2016, a staggering 10.4 million individuals contracted tuberculosis (TB)—only 6.3 million of those individuals received a diagnosis.

Current diagnostic methods for TB require sputum collection and analysis using bacteria staining, culture, and polymerase chain reaction (PCR) in hospital laboratories, which makes accessibility to diagnostic testing harder for those living in underserved rural communities and outpatient clinics. However, investigators from George Mason University (GMU) have developed a new diagnostic tool for TB, a sensitive, noninvasive urine test.

Reportedly, the test can detect TB in all individuals, even those without HIV. Attempts to develop such a test have been made in the past; however, past tests have lacked sufficient sensitivity; they were only able to detect TB in patients who were severely immunocompromised by advanced HIV infection.

The surface of TB bacteria is “coated” with several sugar molecules, all attached to a protein; the coating of the bacteria is thought to be a defense mechanism against immune system response. Lipoarabinomannan (LAM), a sugar molecule which has previously been identified to be a key player in TB infection, is one of the sugar molecules that coats the bacteria. The investigators involved in this research “reasoned that LAM would be shed by tuberculosis bacteria in patients with active disease,” according to a fact sheet provided to the press. “The TB LAM molecule shed from living or dead bacteria enters the bloodstream, is filtered through the kidneys, and accumulates in the urine of the patient.”

The results of past research showed that the concentration of LAM in patients with active TB disease was low enough that it was “difficult or impossible” for investigators to detect. Therefore, for this study, GMU investigators turned to a new chemistry combined with nanotechnology. A key aspect of the study was the discovery of a dye molecule that was able to bind and capture the LAM molecule. The investigators then introduced the dye into nanoparticles, which served as “open mesh cages” that when mixed with urine, could “trap” LAM molecules in the patient’s urine. After inserting the dye, the investigators probed the content of the nanoparticles for captured LAM molecules, which allowed them to not only detect LAM, but also measure its concentration.

By applying this special dye chemistry with this new nanotechnology, the investigators developed a highly sensitive urine test at least 100 times more sensitive than previous tests have shown.

After verifying the test’s sensitivity and specificity, the investigators applied the test to urine samples collected from hospitalized patients in Peru who had culture-positive as well as sputum-stain positive active TB infection. Their findings? The test demonstrated high sensitivity and specificity for this patient population.

The investigators also “compared the bacterial burden determined by means of sputum staining and measure of clinical disease severity by coughing and weight loss to the levels of LAM in the urine by the test,” according to the fact sheet. They found a correlation between TB disease severity and LAM concentration in urine indicating that patients who had more LAM in their urine were suffering from more severe disease.

Furthermore, the investigators were also able to show that their technology was highly versatile, that it could also be used to detect cytokines and other antigens present in urine that were previously undetectable in the past because of their low concentrations.

“In this paper, we demonstrated that with an appropriate technology it is possible to detect with high sensitivity and specificity antigens deriving from Mycobacterium tuberculosis in the urine of TB patients and that the antigen level is correlated with measures of disease severity such as a cough, bacterial burden, weight loss,” corresponding author Alessandra Luchini, PhD, assistant professor at GMU told Contagion ®. “This opens the way for exploring novel kinds of proteins shed by the bacterium in the human host and possibly associated with the physiologic state of the bacterium. These proteins might not be represented in culture in vitro. We expect that such proteins might be different before and after therapy, and in different tissues.”

Because the study consisted of only 100 patients, the investigators are currently in the process of analyzing an additional 1200 patient samples to further extend and validate the results expressed in the study. They are also looking into using the new nanotechnology as a means of discovering a large set of “new, unbiased TB markers, different than previous historical TB markers derived from artificial laboratory culture conditions, in the urine of patients with active TB in rural populations,” according to the fact sheet.

The detection of TB biomarkers that were previously undetectable could provide fruitful insights that may help the world get a leg-up in the fight against TB.